Research programme: Brain disorders therapeutics - Ildong Pharmaceuticals
Latest Information Update: 20 Oct 2015
At a glance
- Originator Ildong Pharmaceutical
- Mechanism of Action Amyloid precursor protein secretase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain disorders
Most Recent Events
- 20 Oct 2015 Preclinical trials in Brain disorders in South Korea (unspecified route)
- 20 Oct 2015 Ildong Pharmaceuticals has patent protection for BACE inhibitors in South Korea